



Arcellx, Inc (ACLX US)

COMPANY DESCRIPTION

Founded in 2014 as *Encarta Therapeutics*, Arcellx, Inc is a **clinical-stage cancer-focused biotechnology company, headquartered in Gaithersburg, MD**. Arcellx develops cell therapies for multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Arcellx has a broad pipeline with the lead product candidate in Phase 2 trial and others in discovery and preclinical phases. 🟢

BUSINESS MODEL


Arcellx has not generated any revenue from product sales but is expected to receive collaboration revenue from partnership with Kite, a Gilead company. 🟢

IPO HISTORY


On **02/04/2022**, Arcellx began trading on the Nasdaq Global Select Market led by BofA Securities. The biotechnology company offered 8.25 million shares, at **\$15.00 per share**, low-end of its expected price range (\$15-\$17). Arcellx was valued at ca. \$657 million at offer with the 15% over-allotment option fully exercised. The shares opened at \$19.00 and closed the first day at \$16.80 (▲12.00%). 🟢

Arcellx, Inc was included in the IPOX® 100 U.S. Index (ETF: FPX US, FPX LN) on 12/19/2022 and currently weighs ca. 0.12% of the portfolio. 🟢

HISTORICAL PERFORMANCE



GROWTH OUTLOOK



Stage of Development						
Indication	Platform	Discovery/ Preclinical	Phase 1	Phase 2	Phase 3	Partnered
Clinical and Preclinical Pipeline						
Multiple Myeloma	ddCAR	IMMagine-1 pivotal/ CART-ddBCMA				
	ddCAR	IMMagine-2 (earlier lines) / CART-ddBCMA				
	ARC-SparX	ACLX-001: BCMA*				
AML/MDS	ARC-SparX	ACLX-002: CD123				
	ARC-SparX	ACLX-003				
Solid Tumors	ARC-SparX	SCLC				
	ddCAR	HCC				

Multiple Myeloma IMCAR - FDA End-of-Phase 1 meeting IMCAR - ASH 2021 Data Update ARC-SparX - Initiate Phase 1 Enrollment in ACLX-001 IMCAR - Present Data Update IMCAR - Present Data Update IMCAR - Initiate Pivotal Study IMCAR - Partnered lead clinical program with Kite ARC-SparX - Present interim clinical data from ACLX-001 IMCAR - Initiate IMMagine-2, earlier line clinical trial IMCAR - Anticipated BLA filing for the treatment of BCMA AML/MDS ARC-SparX - Initiate ACLX-002 Phase 1 clinical trial in AML/MDS	100% ORR 71% CR/SCR Overall response rate (ORR) per IMiD across both dose levels, deep and durable responses observed in patients with poor prognostic factors 30 patients at least 10 months follow-up and are evaluable for efficacy 100% CR/CR, 71% CR/SCR, 100% CR/CR	Phase 1 Study Preliminary Results 115M (+/- 10) Cells RP2D Ongoing Phase 1 expansion at 100 (+/- 20) million CAR+ T cells given favorable safety profile observed to date and 100% ORR 3 dose levels studied (100 million (+/- 20) and 300 million (+/- 20) CAR+ T cells). Median dose for dose level 3 was 100 million CAR+ T cells. MTD not reached.	0% Grade 3 CRS RP2D Toxicities including CRS and ICANS have been manageable at both dose levels 30 patients at 100 million CAR+ T cells had no CRS or ICANS observed to date. No patients at 300 million CAR+ T cells had CRS or ICANS observed to date.
--	---	---	---

INDUSTRY COMPARISON

COMPANY	STOCK SYMBOL	IPO/SPIN-OFF DATE	INITIAL RETURN	OFFER TO DATE (TR)	2023 YTD (PR)	BETA TO BENCHMARK	CASH and CASH EQUIVALENTS (MILLIONS)	R&D EXPENSE (Millions)	EPS
ARCELLX	ACLX US	02/04/2022	12.00%	106.87%	0.16%	0.45	104.6	46.883	-\$145.55

Most of Arcellx's competitions come from well-established specialty pharmaceutical companies and biotechnology companies, academic research institutions and governmental agencies, and public and private research institutions with large scales and better fundings.

Some direct competitors include **AbbVie, Amgen, Bristol-Myers Squibb, GSK, Johnson & Johnson, Legend, Novartis, Pfizer, and Regeneron**.

Data as of January 3rd 2023.